These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9279159)

  • 41. 13Carbon mixed triglyceride breath test and pancreatic enzyme supplementation in cystic fibrosis.
    Amarri S; Harding M; Coward WA; Evans TJ; Weaver LT
    Arch Dis Child; 1997 Apr; 76(4):349-51. PubMed ID: 9166030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fibrosing colonopathy associated with cysteamine bitartrate delayed-release capsules in cystinosis patients.
    Kishk OA; Kim I; Cheng C; Summan M; Muñoz MA
    Pediatr Nephrol; 2024 Aug; 39(8):2429-2433. PubMed ID: 38462547
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of malabsorption in cystic fibrosis: influence of recent developments on clinical practice.
    Littlewood JM
    Postgrad Med J; 1996 Mar; 72 Suppl 2():S56-62; discussion S59-62. PubMed ID: 8869184
    [No Abstract]   [Full Text] [Related]  

  • 44. [Comparative study of the effect of kreon and cotazyme forte in children with cystic fibrosis].
    Zsíros J; Sólyom E
    Orv Hetil; 1988 May; 129(19):995-9. PubMed ID: 3290773
    [No Abstract]   [Full Text] [Related]  

  • 45. Incidence of distal intestinal obstruction syndrome in cystic fibrosis.
    Rosenstein BJ; Langbaum TS
    J Pediatr Gastroenterol Nutr; 1983 May; 2(2):299-301. PubMed ID: 6553601
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fibrosing colonopathy in cystic fibrosis: results of a case-control study.
    Kapadia C
    Gastroenterology; 1996 Jul; 111(1):260-1. PubMed ID: 8698212
    [No Abstract]   [Full Text] [Related]  

  • 47. Fibrosing Colonopathy Presenting in a Patient with Cystinosis.
    Fiore D; Sohini V; Mileti E; Fiore N
    JPGN Rep; 2023 Aug; 4(3):e321. PubMed ID: 37600607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidence of fibrosing colonopathy with pancreatic enzyme replacement therapy in patients with cystic fibrosis.
    Chiuve SE; Fife D; Leitz G; Peterson C; Campbell NM; Rennig A; Rodrigues L; Decktor D; Dowd C; Marshall BC; Borowitz D
    J Cyst Fibros; 2023 Nov; 22(6):1017-1023. PubMed ID: 37880023
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pancreatic enzyme replacement therapy in cystic fibrosis: Australian guidelines. Pediatric Gastroenterological Society and the Dietitians Association of Australia.
    Anthony H; Collins CE; Davidson G; Mews C; Robinson P; Shepherd R; Stapleton D
    J Paediatr Child Health; 1999 Apr; 35(2):125-9. PubMed ID: 10365346
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ulcerative type of colitis associated with the use of high strength pancreatic enzyme supplements in cystic fibrosis.
    Ablin DS; Ziegler M
    Pediatr Radiol; 1995; 25(2):113-5; discussion 115-6. PubMed ID: 7596655
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nutritional management and pancreatic enzyme therapy in cystic fibrosis patients: state of the art in 1987 and projections into the future.
    George DE; Mangos JA
    J Pediatr Gastroenterol Nutr; 1988; 7 Suppl 1():S49-57. PubMed ID: 3042940
    [No Abstract]   [Full Text] [Related]  

  • 52. [Fibrosing colonopathy, an increasing complication of cystic fibrosis].
    Gómez Morales L; García Morillo S; Herrera Justiniano JM; Avila Polo R
    Rev Clin Esp; 2011 Jan; 211(1):63-4. PubMed ID: 21194685
    [No Abstract]   [Full Text] [Related]  

  • 53. Colonic strictures in patients with cystic fibrosis: results of a survey of 114 cystic fibrosis care centers in the United States.
    Freiman JP; FitzSimmons SC
    J Pediatr Gastroenterol Nutr; 1996 Feb; 22(2):153-6. PubMed ID: 8642487
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypoalbuminemia at diagnosis as a marker for severe respiratory course in infants with cystic fibrosis identified by newborn screening.
    Abman SH; Reardon MC; Accurso FJ; Hammond KB; Sokol RJ
    J Pediatr; 1985 Dec; 107(6):933-5. PubMed ID: 3851839
    [No Abstract]   [Full Text] [Related]  

  • 55. Indomethacin and pancreatic enzymes synergistically damage intestine of rats.
    Kimura RE; Arango V; Lloyd-Still J
    Dig Dis Sci; 1998 Oct; 43(10):2322-32. PubMed ID: 9790472
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-strength pancreatic enzyme supplements and large-bowel stricture in cystic fibrosis.
    Oades PJ; Bush A; Ong PS; Brereton RJ
    Lancet; 1994 Jan; 343(8889):109. PubMed ID: 7505872
    [No Abstract]   [Full Text] [Related]  

  • 57. Fibrosing colonopathy in a man with cystic fibrosis on pancreatic enzyme supplements.
    Jain S; Subramony C; Blanchard K; Petro M; Minocha A
    Indian J Gastroenterol; 2005; 24(6):238. PubMed ID: 16424618
    [No Abstract]   [Full Text] [Related]  

  • 58. Desensitization to pancreatic enzyme intolerance in a child with cystic fibrosis.
    Chamarthy LM; Reinstein LJ; Schnapf B; Good RA; Bahna SL
    Pediatrics; 1998 Jul; 102(1):e13. PubMed ID: 9651465
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cystic fibrosis colonopathy.
    Lloyd-Still JD; Beno DW; Kimura RM
    Curr Gastroenterol Rep; 1999 Jun; 1(3):231-7. PubMed ID: 10980955
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes.
    van Velzen D
    Lancet; 1995 Aug; 346(8973):499-500. PubMed ID: 7543642
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.